Form 4: Heron Therapeutics Director Granted 53,960 RSUs

Heron Therapeutics Director Sharmila Dissanaike was granted 53,960 restricted stock units, vesting fully on January 30, 2027.

Summary

• Director Sharmila Dissanaike of Heron Therapeutics, Inc. was granted 53,960 shares of common stock.
• These shares were granted as restricted stock units (RSUs) with a transaction date of January 30, 2026, and a grant price of $0 per share.
• The RSUs are scheduled to vest in full on January 30, 2027.
• Each restricted stock unit represents a contingent right to receive one share of common stock.
• Following this transaction, Dissanaike beneficially owns 53,960 shares directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard corporate governance practices where director compensation includes equity, aligning their interests with the company's long-term success.

Positives

• The grant of restricted stock units to a director aligns management incentives with shareholder interests.
• The equity grant demonstrates continued commitment of a director to the company's long-term success.

Negatives

• The director will not realize the value of the shares until the vesting date in January 2027.
• Potential for minor dilution for existing shareholders upon the full vesting of the RSUs.

Risks

• The ultimate value of the restricted stock units is contingent on the future market price of Heron Therapeutics, Inc. common stock.
• The RSUs may be forfeited if the director's service to the company terminates prior to the full vesting date.

Future Outlook

The grant of restricted stock units with a future vesting date indicates a long-term incentive for the director, aligning their interests with the company's future performance through January 2027.

Industry Context

StockSavvy.ai notes that equity grants, particularly restricted stock units, are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to retain talent and align their long-term interests with shareholder value creation. This practice is standard across companies like Amgen or Gilead Sciences, where performance-based equity is a significant component of total compensation.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) at a $0 price is a standard practice for equity compensation in many industries, including biotech, similar to grants observed at companies like Regeneron Pharmaceuticals or Vertex Pharmaceuticals for their non-employee directors.
• The vesting schedule, a single full vest after approximately one year, is a common structure for director RSU grants, designed to provide a long-term incentive without overly complex performance conditions often seen in executive compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting, but also increased alignment of director's interests with shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Vesting of 53,960 restricted stock units on January 30, 2027.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director, which is a standard compensation practice and does not provide new information that would significantly alter the investment thesis for Heron Therapeutics. It indicates continued director involvement and alignment but does not suggest a strong buy or sell signal based solely on this filing.

Keywords

Heron Therapeutics, HRTX, Restricted Stock Units, RSU, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Stock Vesting